SOLANA BEACH, Calif., April 2, 2025 /PRNewswire/ -- Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. ("Zydus Group"), is pleased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback